Skip to main content

Table 3 Organ-specific tumor response (n = 140)

From: Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study

Sites CR PR SD ORR DCR
Liver (n = 129) 9 7.0% 16 12.4% 40 31.0% 19.4% 50.4%
Thrombosis (n = 81) 2 2.5% 4 4.9% 25 30.9% 7.4% 38.3%
Lung (n = 15) 2 13.3% 3 20.0% 3 20.0% 33.3% 53.3%
Lymph node (n = 7) 0 0.0% 1 14.3% 1 14.3% 14.3% 28.6%
Peritoneum (n = 5) 1 20.0% 1 20.0% 0 0.0% 40.0% 40.0%
Bone (n = 5) 0 0.0% 0 0.0% 1 20.0% 0.0% 20.0%
Adrenal gland (n = 4) 0 0.0% 2 50.0% 0 0.0% 50.0% 50.0%
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease control rate